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with notable resource utilization, including inpatient admissions. Average total 
per patient costs associated with potential AEs constituted over 10% of total 
costs.  
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UNITED STATES  
Wang L1, Huang A1, Li L1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To assess the clinical characteristics and economic burden of 
patients diagnosed with the hepatitis C virus (HCV) in the U.S. veteran 
population. METHODS: A retrospective database analysis was performed using 
the Veterans Health Administration (VHA) Medical SAS Datasets from October 1, 
2005 to May 31, 2012. All U.S. veteran beneficiaries diagnosed with HCV were 
identified using International Classification of Disease 9th Revision Clinical 
Modification (ICD-9-CM) diagnosis codes 070.41, 070.44, 070.51, 070.54, and 
V02.62. Comorbidities and other clinical conditions were assessed for the 12-
month baseline period. Health care resource utilization and costs were assessed 
for the 12-month follow-up period. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure cost, and 
utilization distribution in the sample. RESULTS: A total of 146,161 veterans were 
diagnosed with HCV during the study period. Among the 10 most common 
baseline comorbidities, hypertension was the only condition comprising of more 
than 20% of patients. Patients were also diagnosed with comorbid lumbago 
(8.26%), presbyopia (3.93%) and backache (3.80%), which are common in the 
elderly population. During the baseline period, 4172 patients (or approximately 
3% of the patient population) had Albumin test results of <3.0 mg/dl. 15.03% of 
patients had Prolonged Prothrombin Time Test results of >3.0 seconds. 
Omeprazole (16.06%), lisinopril (15.86%) and hydrochlorothiazide (10.88%) were 
the most commonly prescribed medications within 60 days of initial disease 
identification. Inpatient (26.84%), emergency room (ER) (30.06%), office (99.78%), 
outpatient (99.81%) and pharmacy visits (93.65%) were calculated. Health care 
utilizations translated to the following health care expenses: inpatient ($9,841, 
SD $38,442), ER ($393, SD $1,042), office visit ($9,587, SD $13,035), outpatient 
($10,169, SD $13,599), and pharmacy costs ($1,771, SD $4,703). CONCLUSIONS: 
HCV treatment is complicated by the presence of comorbidities such as 
hypertension. Further analysis of complicated comorbid conditions is required to 
improve the overall burden of illness of HCV patients.  
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OBJECTIVES: To assess the population-level impact and cost-effectiveness of 
universal Hepatitis A vaccination of children in United States as recommended 
by Advisory Committee on Immunization Practices (ACIP) in 2006 compared with 
the prior ACIP regional policy of routine vaccination of children living in states 
with high hepatitis rates. METHODS: We developed a population-dynamic model 
of Hepatitis A to evaluate the public health- and economic- impacts of two-dose 
Hepatitis A vaccination of children 12 and 18 months of age. The dynamic model 
was fitted to Hepatitis A seroprevalence from the National Health and Nutrition 
Examination Survey (NHANES II and III) and reported incidence from the 
National Notifiable Diseases Surveillance System (1980–1995). We used a societal 
perspective and projected outcomes over the period 2006–2106 (a 100-year time 
horizon). Both costs and quality-adjusted life years (QALYs) were discounted at 
3% per year. RESULTS: Universal Hepatitis A vaccination prevented 144,375 
infections, 63,153 outpatient visits, 2,727 hospitalizations, and 96 deaths 
incrementally on an average annual basis when compared to the regional 
vaccination policy. Herd protection played an important role in reducing 
infections as it accounted for prevention of nearly 76% of deaths and 50% of 
outpatient visits and hospitalizations. Ignoring herd protection, vaccination 
prevented 90,845 infections, 34,353 outpatient visits, 1,438 hospitalizations, and 
23 deaths annually. Taking herd protection into account, universal vaccination 
was cost saving, whereas without it the ICER was $41,712/QALY. CONCLUSIONS: 
Universal two-dose vaccination of children led to significant reductions in 
Hepatitis A mortality and morbidity. Consequently, universal vaccination was 
cost saving compared with a regional vaccination policy. Herd protection effects 
of vaccination programs had a significant impact on hepatitis A mortality, 
morbidity, and cost-effectiveness ratios. Because of their ability to capture the 
natural phenomenon of herd protection, dynamic models have significant utility 
for economic evaluation of Hepatitis A vaccination programs.  
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ECONOMIC ASSESSMENT OF HIGH-RISK VERSUS UNIVERSAL PEDIATRIC PCV13 
VACCINATION PROGRAMS IN COSTA RICA  
Roberts CS1, McGarry L2, Gilmore K2, Lutz MA3, Strutton DR4 
1Pfizer, New York, NY, USA, 2OptumInsight, Cambridge, MA, USA, 3Pfizer Central America and 
the Caribbean, San Jose, Costa Rica, 4Pfizer, Inc., Collegeville, PA, USA  
OBJECTIVES: In 2011 PCV13 replaced PCV7 in Costa Rica’s National 
Immunization Program, however, continuation of the program is being evaluated 
based on considerations of cost-effectiveness. We evaluated the cost-
effectiveness of continuing universal PCV13 infant vaccination versus limiting 
vaccination to high-risk children. METHODS: We used a decision-analytic 
Markov model to assess the impact of alternative pediatric PCV13 vaccination 
strategies: universal versus targeted to high-risk children only. For the universal 
strategy, outcomes are assessed for the entire Costa Rican population to capture 
indirect (herd) effects that accrue in the unvaccinated individuals. The model 
was populated using Costa Rican epidemiologic data and estimates from other 
published sources. Estimates of PCV13 effectiveness were extrapolated from 
observed PCV7 data, using assumptions regarding serotype prevalence and 
PCV13 protection against 6 additional serotypes. Coverage was assumed to be 
the same for high-risk and the general population vaccination strategies. 
Outcome measures were incidence of invasive pneumococcal disease (IPD), 
pneumonia and acute otitis media (AOM); mortality, and net medical-care costs 
over 10 years from the societal perspective. RESULTS: Compared to no 
vaccination, the high-risk program would prevent 100 cases of IPD, 420 cases of 
hospitalized pneumonia (HP), 330 cases of non-hospitalized pneumonia (NHP), 
and 26,300 cases of AOM, and provide net savings of $460,000 over 10 years. 
Universal vaccination would prevent 2,200 cases of IPD, 14,800 cases of HP, 
24,500 cases of NHP, and 367,000 cases of AOM for net savings of $34.8 million. 
Compared to the high-risk program, universal vaccination would provide net 
savings of $34.3 million. Excluding indirect effects, universal vaccination results 
in ICERs of $4,400 and $5,600 per QALY gained compared with no vaccination 
and high-risk vaccination, respectively. CONCLUSIONS: Both high-risk and 
universal infant vaccination with PCV13 are cost-effective in Costa Rica; 
universal vaccination dominates both no vaccination and high risk vaccination 
due to indirect effects.  
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OBJECTIVES: Complicated skin and soft tissue infections (cSSTI) are commonly 
encountered in the community and nosocomial settings. Methicillin-resistant S. 
aureus (MRSA) has become the predominant pathogen in cSSTI raising health 
care costs and reducing positive health outcomes. The aim of this analysis is to 
estimate the cost-effectiveness of linezolid in the treatment of cSSTI in Chile 
from the private payer’s perspective. METHODS: A decision tree was built  
to estimate the incremental cost-effectiveness ratio (ICER) of linezolid (1200 
mg/day) compared with vancomycin (2 mg/day), daptomycin (350 mg/day) and 
tigecycline (100 mg/day). Within a time horizon of 28 days, the model simulates 
health outcomes and costs for all alternatives at the Provisional Health 
Institutions – ISAPRE. Only direct medical costs were considered. Effectiveness 
measures were: quality-adjusted life-year gained (QALY’s) and percentage of 
patients cured. Efficacy, safety and utility values were collected from literature 
review. Resource use and medical costs (drug acquisition, inpatient stay, health 
care professional visits, and lab tests) were taken from Chilean private 
institutions. Costs are expressed in 2012 US$. RESULTS: The total expected  
costs for per patient were: linezolid US$12,905.1, vancomycin US$13,039.9, 
daptomycin US$16,067.3 and tigecycline US$17,038.5. Treatment with linezolid 
was associated with a shorter length of stay at the intensive care unit (7 days on 
average) which reduced significant treatment costs due the likelihood of 
switching from intravenous to oral administration (5 days savings on average). 
Results for each alternative in terms of QALYs were: linezolid 0.063, vancomycin 
0.060, daptomycin 0.061 and tigecycline 0.059. The percentage of patients  
cured for each alternative was: linezolid 84.4%; vancomycin 74.7%; daptomycin 
78.1% and tigecycline 70.4%. Model result suggests that linezolid would be 
dominant compared to vancomycin, daptomycin and tigecycline. 
CONCLUSIONS: Despite its higher acquisition cost, linezolid would be a cost-
saving alternative in the treatment of cSSTI in the Chilean Provisional Health 
Institutions (ISAPRE).  
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OBJECTIVES: Complicated skin and skin structure infections (cSSSIs) are 
primarily caused by gram-positive bacteria, including Staphylococcus aureus and 
β-hemolytic streptococci. The impact of cSSSIs caused by Methicillin-resistant S. 
aureus (MRSA) has been associated with an increase in length of hospital stay 
and resource use. The aim of this analysis is to estimate the cost-effectiveness of 
linezolid in the treatment of cSSTI at the Chilean public setting. METHODS: A 
decision tree was built to estimate the incremental cost-effectiveness ratio of 
linezolid (1200 mg/day) compared to vancomycin (2 mg/day), daptomycin (350 
mg/day) and tigecycline (100 mg/day). The payer’s perspective (National Fund of 
Health – FONASA) was used, including inpatient medical costs only. The time 
horizon was 28 days. Effectiveness was measured with quality-adjusted life-year 
(QALY’s) and the percentage of patients cured. Efficacy, safety and utility values 
were retrieved from literature. Resource use and costs (drug acquisition, 
inpatient stay, health care professional visits, and lab tests) were taken from 
Chilean public health care institutions. Costs are expressed in 2012 USD. 
RESULTS: The total expected costs per patient were: linezolid US$3489.0, 
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vancomycin US$3909.2, daptomycin US$6131.2 and tigecycline US$5509.0. The 
treatment with linezolid was associated with a shorter stay in the intensive care 
unit (7 days on average) which reduces the cost of treatment because it allowed 
the switch from intravenous to oral administration (5 days on average). Results 
for each alternative in QALYs were: linezolid 0.063, vancomycin 0.060, 
daptomycin 0.061 and tigecycline 0.059. The results for each alternative in terms 
of percentage of patients cured were: linezolid 84.4%, vancomycin 74.7%, 
daptomycin 78.1% and tigecycline 70.4%. The model results indicate that 
linezolid is dominant compared to vancomycin, daptomycin and tigecycline. 
Probabilistic sensitivity analyses showed the robustness of these findings. 
CONCLUSIONS: Linezolid is a cost-saving alternative in the treatment of cSSTI in 
the Chilean National Fund of Health (FONASA).  
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OBJECTIVES: The objective of this research is to evaluate the cost-effectiveness 
of linezolid 600mgBID(LI), vancomycin 1gBID(VA) and teicoplanin 400mgBID(TE) 
in the treatment of nosocomial pneumonia caused by MRSA under the private 
health care system perspective. METHODS: To compare the options, a decision 
tree model was built considering an arm per treatment option, from which 
patients could respond to the initial treatment and continue to maintenance 
treatment using the same antibiotics, or do not respond, and repeat the 
treatment with assumed 50% chance to use one of the other two antibiotics. 
Clinical or microbiological effectiveness could be used as determinants of 
response. Effectiveness measures were mortality, clinical and microbiological 
responses, calculated by an indirect comparison of a literature systematic 
review. Hospitalization days were evaluated. Only direct costs were considered, 
and were obtained from CBHPM2010 for medical procedures, CMED 
December2012, considering X-factory price plus 18% tax for medications  
and BRASINDICE December2012 for materials. Values were represented in 
2012USD. A time horizon of 1 year was considered. RESULTS: Clinical response 
rates were 66.5%(VA), 68.3%(TE), 72.6%(LI), microbiological response rates were 
56.1%(VA), 55.9%(TE), 64.4%(LI), mortality rates were 15.74%(VA), 13.56%(TE), 
10.13%(LI). If clinical response was considered as a determinant of success, the 
treatment costs would be US$33,190.76(VA), US$41,657.71(TE), US$27,036.62(LI), 
hospitalization days would be 41(VA), 39(TE), 26(LI), and if microbiological 
response was considered, the treatment costs would be US$34,597.12(VA); 
US$42,574.61(TE), US$28,514.48(LI) and hospitalization days would be 42(VA), 
40(TE), 28(LI). Incremental cost-effectiveness ratios for TE and LI when compared 
to VA for clinical response were US$470,386.13, -US$100,887.50(dominant),  
and for microbiological response were -US$398,874.67(dominated),  
-US$73,284.78(dominant) respectively. CONCLUSIONS: Compared to 
vancomycin, teicoplanin was either dominated or did not reach cost-
effectiveness considering a willingness to pay of US$32,621.93 (3xBrazilian GDP 
per capita), whereas linezolid was dominant, presenting lower mortality while 
offsetting costs, mainly driven by less hospitalization days at private health care 
services.  
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OBJECTIVES: Aspergillosis is the second cause of invasive fungal infections with 
high mortality rates. The objective of this research is to evaluate the cost-
effectiveness of amphotericin B(AB) 1.5mg/kg/day, amphotericin B liposomal(AL) 
3mg/kg/day, caspofungin(CA) 50mg/day, voriconazol 8mg/kg/day(VO) including 
maintenance oral Voriconazol 400mg/day scheme in the treatment of 
aspergillosis under the Brazilian public health care system perspective. 
METHODS: To compare the options, a decision tree model was built considering 
sequential treatments, from which patients could respond to one initial 
treatment and continue to a maintenance phase of the same medication, or do 
not respond due to either inefficacy or adverse events and switch treatments 
with assumed equal chance to use one of the other options. Effectiveness 
measures were mortality, clinical response and days of hospitalization, 
calculated by indirect comparison of a literature systematic review. Only direct 
costs were considered, and were obtained from the publicly available databases 
of DATASUS. Values were represented in 2012USD. A time horizon no longer 
than 4 weeks was considered, thus discounting was not applied. One-way 
sensitivity analysis considered de-hospitalization in maintenance phases while 
using oral Voriconazol. RESULTS: Clinical response rates were 36.40%(AB), 
34.60%(AL), 34.20%(CA), 56.67%(VO), mortality rates were 50.90%(AB), 48.70%(AL), 
44.70%(CA), 34.10%(VO) and hospitalization days were 26.35(AB), 24.68(AL), 
25.33(CA), 22.55(VO). Expected treatment costs were 18,380.91USD(AB), 
53,076.12USD(AL), 27,145.04USD(CA) and 24,510.88USD(VO). Considering AB as 
the baseline for cost-effectiveness, VO presented an incremental cost-
effectiveness ratio(ICER) of 30,241.60 while other options were dominated with 
higher costs and lower effectiveness. If de-hospitalization was considered, VO 
arm would sum 14.62 hospitalization days, treatment cost of 23,299.90USD and 
an ICER of 24,267.34USD. CONCLUSIONS: Assuming a willingness to pay of 
32,621.93USD (3 times Brazilian 2011GDP per capita), VO was the only cost-
effective option compared to AB, additionally presenting lower mortality and less 
hospitalization days while allowing early de-hospitalization at public health care 
services.  
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OBJECTIVES: Strategies for monitoring antiretroviral therapy (ART) include 
clinical assessment, CD4 testing, and viral load (VL) testing. Although benefits of 
VL monitoring have been established, it is considered too expensive to 
implement in low-income settings. Several studies have found varying levels of 
cost-effectiveness (CE) of VL monitoring. We reviewed the studies and evaluated 
their quality to identify gaps in evidence of potential CE of VL testing in low-
income settings. METHODS: We performed a systematic review of studies with a 
cost analysis using a Medline search from 1980-2012 with keywords ‘cost’, 
‘economic’, ‘viral load’, and ‘HIV’. We assessed study quality using the validated 
Quality of Health Economic Scales (QHES) questionnaire and the Drummond 
criteria. RESULTS: We identified and included eight studies. QHES scores ranged 
from 44 to 83 (on a scale of 0-100). Two methodologically strong studies used 
Markov models, and three used high quality cohort data. One study was 
performed among children, one used clinical trial data that may not be 
generalizable, and one did not include a CD4 monitoring strategy. Incremental 
CE ratios ranged from $86/life-year to $68,698/quality-adjusted life-year and were 
most sensitive to cost of VL test kits, followed by treatment failure rates and 
utilities. Two studies found VL testing to be CE (<3 times gross domestic product 
(GDP)/capita), and three found it to be highly CE (<1 times GDP/capita). Only one 
study included a societal perspective, which found VL monitoring to be cost 
saving. CONCLUSIONS: This evidence suggests that VL testing may be CE in low-
income settings. The five studies that were methodologically strong and utilized 
high quality data found VL monitoring CE or highly CE. Reduced costs of VL test 
kits may further enhance CE. Future studies are needed to address 
methodological and data quality issues as well as use of a societal perspective.  
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OBJECTIVES: Community acquired pneumonia (CAP) still represents an 
important disease in Mexico. The study of both economic and clinical outcomes 
of treatments remains relevant. The aim of this study was to assess the 
consequences of the use of antibiotics to treat CAP, from the perspective of 
Instituto Mexicano del Seguro Social (IMSS). METHODS: A decision tree model 
that considers clinical success and failure either whit first and second line 
treatments, presentation or not of adverse events (AE´s), as well as death was 
developed. The antibiotics considered in the assessment were: clarithromycin 
(1,000 mg/day), levofloxacin (1,000 mg/day), ceftriaxone (1,000 mg/day), 
cefuroxime (1,500 mg/day), moxifloxacin (400 mg/day) and gemifloxacin (320 
mg/day). The last option is not listed in IMSS formulary. Clinical data were 
extracted from international literature. Effectiveness measures were clinical 
success rate and length of stay (LOS). The model considered direct medical costs 
(2012 US$): drugs, diagnostic tests, physician visits, LOS, emergency room and 
intensive care unit; cost were extracted from institutional sources. Resource use 
for CAP was extracted from clinical files (n=94 adult patients) treated at one IMSS 
hospital, whereas resource use for AE´s treatment was obtained through expert 
opinion (panel). One-way sensitivity analysis and acceptability curves were 
performed. RESULTS: The alternative that presented the most favorable 
pharmacoeconomic profile was gemifloxacin ($3237 per patient, 95.3% of success 
rate and 6.22 days of LOS), followed by levofloxacin and clarithromycin, with 
marginal differences in clinical success but around $1600 of incremental cost. 
The alternative with the less favorable profile was moxifloxacin: $1784.52 of 
incremental cost, -8.8% of clinical success and +6.6 days of LOS regarding 
gemifloxacin. The results were robust to +10% acquisition cost and +5% AE´s 
incidence for gemifloxacin. CONCLUSIONS: Alternatives with potential to 
promote savings in the management of CAP (like gemifloxacin) are valuable, 
which becomes more relevant in contexts with limited resources.  
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OBJECTIVES: Benefits of QIV over trivalent inactivated vaccine (TIV) are 
dependent on the proportion of influenza circulation attributable to influenza-B 
and the extent of vaccine matching with respect to circulating B-lineages. 
Applying the 2000-2010 influenza data from the Health Protection Agency, the 
impact of vaccination with QIV versus TIV on influenza morbidity and mortality 
in the UK was evaluated to estimate potential benefits of QIV if it had been 
available during this time. METHODS: Using current influenza management 
guidance (vaccination of those at-risk and the elderly), a multi-cohort, static, 1-
year decision model was used. Influenza A and B was accounted for separately. 
Vaccine efficacy data was derived from Cochrane Databases (TIV) and meta-
analyses (QIV). The model considers the perspective of the UK National Health 
Service. RESULTS: Using the average influenza-B circulation and vaccine 
